S. Verma

1.5k total citations
20 papers, 450 citations indexed

About

S. Verma is a scholar working on Oncology, Genetics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, S. Verma has authored 20 papers receiving a total of 450 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 6 papers in Genetics and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in S. Verma's work include HER2/EGFR in Cancer Research (6 papers), Breast Cancer Treatment Studies (5 papers) and BRCA gene mutations in cancer (4 papers). S. Verma is often cited by papers focused on HER2/EGFR in Cancer Research (6 papers), Breast Cancer Treatment Studies (5 papers) and BRCA gene mutations in cancer (4 papers). S. Verma collaborates with scholars based in Canada, United Kingdom and United States. S. Verma's co-authors include Alasdair G. W. Hunter, Lauren Humphreys, Linda Surh, Judith Allanson, Mario Cappelli, Diane Logan, Louise Provencher, M. Clemons, Susan Dent and John R. Mackey and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

S. Verma

19 papers receiving 435 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S. Verma Canada 13 217 160 90 70 62 20 450
Eileen Dimond United States 14 226 1.0× 342 2.1× 61 0.7× 205 2.9× 41 0.7× 38 861
Hoa N. Nguyen United States 16 185 0.9× 104 0.7× 21 0.2× 121 1.7× 136 2.2× 37 866
Yoshie Hasegawa Japan 11 217 1.0× 37 0.2× 49 0.5× 66 0.9× 93 1.5× 51 394
LJ Goldstein United States 7 386 1.8× 248 1.6× 10 0.1× 125 1.8× 74 1.2× 30 634
Kara Laing Canada 12 274 1.3× 29 0.2× 29 0.3× 101 1.4× 114 1.8× 26 537
Kyoko Okamura Japan 10 160 0.7× 33 0.2× 43 0.5× 170 2.4× 136 2.2× 22 513
Paula Poikonen‐Saksela Finland 11 346 1.6× 65 0.4× 12 0.1× 61 0.9× 92 1.5× 39 516
Terrence P. Cescon United States 10 175 0.8× 115 0.7× 10 0.1× 53 0.8× 77 1.2× 18 332
Patrick Cobb United States 14 301 1.4× 66 0.4× 8 0.1× 96 1.4× 105 1.7× 43 476
Byung Kyun Ko South Korea 15 141 0.6× 47 0.3× 21 0.2× 117 1.7× 70 1.1× 37 429

Countries citing papers authored by S. Verma

Since Specialization
Citations

This map shows the geographic impact of S. Verma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Verma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Verma more than expected).

Fields of papers citing papers by S. Verma

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Verma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Verma. The network helps show where S. Verma may publish in the future.

Co-authorship network of co-authors of S. Verma

This figure shows the co-authorship network connecting the top 25 collaborators of S. Verma. A scholar is included among the top collaborators of S. Verma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Verma. S. Verma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
André, François, Salomon M. Stemmer, G. N. Hortobagyi, et al.. (2016). Ribociclib + letrozole for first-line treatment of HR+, HER2− ABC: efficacy, safety, and pharmacokinetics. European Journal of Cancer. 69. S7–S7. 4 indexed citations
4.
5.
Samson, André, et al.. (2013). Living with the BRCA1 and BRCA2 genetic mutation: Learning how to adapt to a virtual chronic illness. Psychology Health & Medicine. 19(1). 103–114. 15 indexed citations
6.
Samson, André, et al.. (2012). Living with the BRCA genetic mutation: An uncertain conclusion to an unending process. Psychology Health & Medicine. 18(2). 125–134. 31 indexed citations
7.
Verma, S., et al.. (2012). Advances in the Management of Metastatic Breast Cancer: Options Beyond First-Line Chemotherapy. Current Oncology. 19(2). 91–105. 15 indexed citations
8.
Baribeau, Danielle, et al.. (2011). Management of early-stage breast cancer: Are we headed in the right direction?. Journal of Clinical Oncology. 29(15_suppl). e11039–e11039. 1 indexed citations
9.
Younus, Jawaid, et al.. (2010). Sunitinib Malate for Gastrointestinal Stromal Tumour in Imatinib Mesylate–Resistant Patients: Recommendations and Evidence. Current Oncology. 17(4). 4–10. 30 indexed citations
10.
Lemieux, Julie, M. Clemons, Louise Provencher, et al.. (2009). The Role of Neoadjuvant her2-Targeted Therapies in her2-Overexpressing Breast Cancers. Current Oncology. 16(5). 48–57. 10 indexed citations
11.
Dent, Susan, S. Verma, Jean Latreille, et al.. (2009). The Role of her2-Targeted Therapies in Women with her2-Overexpressing Metastatic Breast Cancer. Current Oncology. 16(4). 25–35. 14 indexed citations
12.
13.
Mackey, John R., M. Clemons, Susan Dent, et al.. (2008). Cardiac Management during Adjuvant Trastuzumab Therapy: Recommendations of the Canadian Trastuzumab Working Group. Current Oncology. 15(1). 24–35. 100 indexed citations
14.
Verma, S., et al.. (2007). Temozolomide for the Treatment of Metastatic Melanoma. Current Oncology. 14(1). 27–33. 30 indexed citations
15.
Petrella, Teresa M., Ian Quirt, S. Verma, et al.. (2007). Single-Agent Interleukin-2 in the Treatment of Metastatic Melanoma. Current Oncology. 14(1). 21–26. 21 indexed citations
16.
Gainford, M. Corona, et al.. (2005). A practical guide to the management of menopausal symptoms in breast cancer patients. Supportive Care in Cancer. 13(8). 573–578. 14 indexed citations
17.
Miles, David, J. O’Shaughnessy, Guadalupe Cervantes, et al.. (2001). Survival benefit with Xeloda (capecitabine)/docetaxel vs docetaxel: analysis of post-study therapy.. Breast Cancer Research and Treatment. 69(3). 287–287. 12 indexed citations
18.
Leyland‐Jones, Brian, Andrew Arnold, Karen Gelmon, et al.. (2001). Pharmacologic insights into the future of trastuzumab. Annals of Oncology. 12. S43–S47. 16 indexed citations
19.
Cappelli, Mario, Linda Surh, Mark Walker, et al.. (2001). Psychological and social predictors of decisions about genetic testing for breast cancer in high-risk women. Psychology Health & Medicine. 6(3). 321–333. 24 indexed citations
20.
Cappelli, Mario, Linda Surh, Lauren Humphreys, et al.. (1999). Psychological and social determinants of women's decisions to undergo genetic counseling and testing for breast cancer. Clinical Genetics. 55(6). 419–430. 97 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eileen Dimond Breakdown of academic impact, for papers by Hoa N. Nguyen Breakdown of academic impact, for papers by Yoshie Hasegawa Breakdown of academic impact, for papers by LJ Goldstein Breakdown of academic impact, for papers by Kara Laing Breakdown of academic impact, for papers by Kyoko Okamura Breakdown of academic impact, for papers by Paula Poikonen‐Saksela Breakdown of academic impact, for papers by Terrence P. Cescon Breakdown of academic impact, for papers by Patrick Cobb Breakdown of academic impact, for papers by Byung Kyun Ko
Rankless by CCL
2026